Malignant Vaginal Neoplasm
Associated Genetic Biomarkers
NCI Definition: A primary or metastatic malignant neoplasm involving the vagina. Representative examples include carcinomas and sarcomas. 
Malignant vaginal neoplasms most frequently harbor alterations in TP53, KRAS, RASA1, KMT2D, and JAK2 .
TP53 c.217-c.1178 Missense, TP53 Mutation, TP53 Missense, KRAS Mutation, and KRAS Exon 2 Mutation are the most common alterations in malignant vaginal neoplasm .
There is 1 clinical trial for malignant vaginal neoplasm, of which 1 is open and 0 are completed or closed. Of the trial that contains malignant vaginal neoplasm as an inclusion criterion, 1 is phase 1 (1 open).
TREM1 is the most frequent gene inclusion criterion for malignant vaginal neoplasm clinical trials .
Py159 and pembrolizumab are the most common interventions in malignant vaginal neoplasm clinical trials.
Significant Genes in Malignant Vaginal Neoplasm
ERBB2 is altered in 14.29% of malignant vaginal neoplasm patients .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for malignant vaginal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and malignant vaginal neoplasm as inclusion criteria, 1 is phase 1 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.